Reduction in the risk of mpox infection after MVA-BN vaccination in individuals on HIV pre-exposure prophylaxis: a Spanish cohort study
Authors: Fontán-Vela Mario , Hernando Victoria , Olmedo Carmen , Coma Ermengol , Martínez Montse , Moreno-Perez David , Lorusso Nicola , Vázquez Torres María , Barbas del Buey José Francisco , Roig-Sena Javier , Pastor Eliseo , Galmés Truyols Antònia , Artigues Serra Francisca , Sancho Martínez Rosa María , Latasa Zamalloa Pello , Pérez Martínez Olaia , Vázquez Estepa Ana , José García Rojas Amós , Barreno Estévez Ana Isabel , Sánchez-Migallón Naranjo Alonso , Pérez Martín Jaime Jesús , Peces Jiménez Pilar , Morales Romero Raquel , Castilla Jesús , García Cenoz Manuel , Huerta Huerta Marta , Boone An Lieve Dirk , Macías Ortiz María José , Álvarez Río Virginia , Rodríguez Recio María Jesús , Merino Díaz María , Berradre Sáenz Belén , Teresa Villegas-Moreno María , Limia Aurora , Diaz Asuncion , Monge Susana ,   Spanish MPOX vaccine effectiveness study group
Published: June 2023

Objectives

To assess the effectiveness of at least one-dose of the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine, administered pre-exposure, against mpox virus (MPXV) infection in persons receiving pre-exposure prophylaxis for HIV (HIV-PrEP).

Design

Retrospective cohort, constructed by deterministic linkage of electronic health records.

Setting

15 of 19 regions in Spain (>95% population), between July 12 and December 12, 2022

Participants

Men ≥18 years, receiving HIV-PrEP as of July 12 and with no previous MPXV infection or vaccination against mpox.

Interventions

On each day, we matched individuals receiving a first dose of MVA-BN vaccine pre-exposure and unvaccinated controls of the same age (±5 years) and region.

Main outcome measures

We estimated the risk of laboratory-confirmed infection with MPXV using a Kaplan-Meier estimator and calculated risk ratios (RR) and vaccine effectiveness (VE=1-RR).

Results

We included 5,660 matched pairs, with a median follow-up of 62 days (interquartile range 24-97). Mpox cumulative incidence was 5.6 per 1,000 (25 cases) in unvaccinated and 3.5 per 1,000 (18 cases) in vaccinated; last case occurred at 63 and 17 days after enrolment, respectively. No effect was found during days 0-6 post-vaccination (VE -38.3; 95% confidence interval (95%CI): -332.7; 46.4), but VE was 65% in ≥7 days (95%CI 22.9; 88.0) and 79% in ≥14 days (95%CI 33.3; 100.0) after vaccination.

Conclusion

At least one dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population. Because the incidence of mpox was decreasing shortly after the vaccination campaign began, we can only assess its effectiveness shortly after vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time.

What is already known on this topic:

MVA-BN vaccination is effective in producing an immune response against mpox virus (MPXV) and has shown clinical efficacy in animal models.

During the current mpox outbreak, observational studies have indicated that MVA-BN vaccines are effective in preventing MPXV infection in real-life.

No individual-based cohort study with proper implementation of causal inference methods, providing the highest quality of evidence with observational data, has been published to date.

What this study adds:

The administration of one dose of MVA-BN vaccine in a high-risk population (men receiving HIV pre-exposure prophylaxis) reduced the risk of MPXV infection by 65% starting 7 days after the administration and by 79% starting 14 days after.

Effectiveness of MVA-BN vaccine was similar in population under 50 years, a group where childhood smallpox vaccination is rare in Spain.

This is the first study to estimate MVA-BN vaccine effectiveness in one of the countries most affected by the mpox outbreak in 2022, with a design and methods providing high quality evidence.